Trinity Biotech to Announce Q2 2024 Financial Results

Rhea-AI Summary

Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, has announced it will release its Q2 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss the results.

Investors and interested parties can access the call through various methods:

• US Toll-Free: 1-877-407-0784
• International: 1-201-689-8560
• Conference ID: 13748426
• Webcast link available
• Call me™ feature: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6

Positive

• Trinity Biotech is maintaining transparency by hosting a quarterly earnings call
• The company offers multiple ways for investors to access the financial results and participate in the call

Negative

• None.

Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET

DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the second quarter 2024 on Wednesday, August 14, 2024 at 8:30 AM ET.

Conference Call Dial-In & Webcast Information

Date:	Wednesday, August 14, 2024
Time:	8:30 AM ET
United States:	1-877-407-0784
International:	1- 201-689-8560
Conference ID:	13748426
Webcast:	webcast link
Call me™:	https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6

About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com

Contact:	Trinity Biotech plc	LifeSci Partners, LLC
	John Gillard	Eric Ribner
	(353)-1-2769800	(1)-646-751-4363
	E-mail: john.gillard@trinitybiotech.com	E-mail: investorrelations@trinitybiotech.com

FAQ

When will Trinity Biotech (TRIB) release its Q2 2024 financial results?

Trinity Biotech (TRIB) will release its Q2 2024 financial results on Wednesday, August 14, 2024.

What time is Trinity Biotech's (TRIB) Q2 2024 earnings call scheduled for?

Trinity Biotech's (TRIB) Q2 2024 earnings call is scheduled for 8:30 AM ET on Wednesday, August 14, 2024.

How can investors join Trinity Biotech's (TRIB) Q2 2024 earnings call?

Investors can join Trinity Biotech's (TRIB) Q2 2024 earnings call by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International), using the Conference ID 13748426, or via the provided webcast link.

What is Trinity Biotech's (TRIB) main business focus?

Trinity Biotech (TRIB) is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors.